Manish Sagar, MD
Professor, Medicine
Biography
Dr. Manish Sagar is a Professor of Medicine at the Chobanian and Avedisian School of Medicine. His laboratory is primarily interested in human immunodeficiency virus type 1 (HIV-1) mucosal HIV-1 transmission and antibodies. One of the focuses is to understand the biological mechanisms for the selection observed during HIV-1 transmission. Even though chronically infected subjects harbor extensive variants during transmission, only a limited number of viruses are acquired by newly infected partners. Genotypic examination of viruses present in the newly infected subject compared to those circulating in the transmitting partner suggests that the observed genetic bottleneck during transmission is not due to random chance. Laboratory studies explore the hypothesis that during transmission there is selection of specific variants with properties that confer fitness for transmission.
Another focus in the lab is to decipher correlate of immune protection. Even though infants are exposed to infected breast milk, only a small proportion (around 30%) acquire HIV-1 from their infected mother in the absence of antiretroviral protection. The lab hypothesizes that maternally acquired antibodies present in the infant prevent HIV-1 acquisition either through neutralization or antibody dependent cellular cytotoxicity against the variants circulating in the maternal breast milk. Defining the immune correlate of protection will have important implications for HIV-1 vaccine design. Their work focuses on understanding HIV-1 envelope and host antibody evolution and impact on disease pathogenesis.
Dr. Sagar has served on numerous committees including NIH study sections and Doris Duke Charitable Foundation Early Career Development Award Review Committee. He is an active member of the Infectious Diseases Society of America (IDSA).
Other Positions
- Professor, Virology, Immunology & Microbiology, Boston University Chobanian & Avedisian School of Medicine
- Member, Genome Science Institute, Boston University
- Graduate Faculty (Primary Mentor of Grad Students), Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences
Education
- Johns Hopkins University School of Medicine, MD
- Columbia University, BS
Publications
- Published on 10/23/2024
Bean DJ, Liang YM, Sagar M. Recent Endemic Coronavirus Infection Associates With Higher SARS-CoV-2 Cross-Reactive Fc Receptor Binding Antibodies. bioRxiv. 2024 Oct 23. PMID: 39484477.
Read at: PubMed - Published on 6/27/2024
Heindel DW, Figueroa Acosta DM, Goff M, Yengo CK, Jan M, Liu X, Wang XH, Petrova MI, Zhang M, Sagar M, Barnette P, Pandey S, Hessell AJ, Chan KW, Kong XP, Chen BK, Mahal LK, Bensing BA, Hioe CE. HIV-1 interaction with an O-glycan-specific bacterial lectin enhances virus infectivity and resistance to neutralizing antibodies. iScience. 2024 Aug 16; 27(8):110390. PMID: 39108723.
Read at: PubMed - Published on 6/12/2024
Bean DJ, Monroe J, Liang YM, Borberg E, Senussi Y, Swank Z, Chalise S, Walt D, Weinberg J, Sagar M. Heterotypic immunity from prior SARS-CoV-2 infection but not COVID-19 vaccination associates with lower endemic coronavirus incidence. Sci Transl Med. 2024 Jun 12; 16(751):eado7588. PMID: 38865483.
Read at: PubMed - Published on 1/3/2024
Heindel DW, Figueroa Acosta DM, Goff M, Yengo CK, Jan M, Liu X, Wang XH, Petrova MI, Zhang M, Sagar M, Barnette P, Pandey S, Hessell AJ, Chan KW, Kong XP, Chen BK, Mahal LK, Bensing BA, Hioe CE. HIV-1 interaction with an O-glycan-specific bacterial lectin enhances virus infectivity and resistance to neutralization by antibodies. Res Sq. 2024 Jan 03. PMID: 36824869.
Read at: PubMed - Published on 10/24/2023
Bean DJ, Monroe J, Liang YM, Borberg E, Senussi Y, Swank Z, Chalise S, Walt D, Weinberg J, Sagar M. Heterotypic responses against nsp12/nsp13 from prior SARS-CoV-2 infection associates with lower subsequent endemic coronavirus incidence. bioRxiv. 2023 Oct 24. PMID: 37961343.
Read at: PubMed - Published on 8/10/2023
Zheng A, Huang N, Bean D, Rayapaneni S, Deeney J, Sagar M, Hamilton JA. Resolvin E1 heals injured cardiomyocytes: Therapeutic implications and H-FABP as a readout for cardiovascular disease & systemic inflammation. Prostaglandins Leukot Essent Fatty Acids. 2023 Oct; 197:102586. PMID: 37604082.
Read at: PubMed - Published on 6/6/2023
Halpin M, Lerner A, Sagar M, Govender P, Shah B, Weinberg J, Sarosiek S, Sloan JM. A prospective, single-center, randomized phase 2 trial of etoposide in severe COVID-19. medRxiv. 2023 Jun 06. PMID: 37333402.
Read at: PubMed - Published on 5/10/2023
Esmaeilzadeh E, Etemad B, Lavine CL, Garneau L, Li Y, Regan J, Wong C, Sharaf R, Connick E, Volberding P, Sagar M, Seaman MS, Li JZ. Autologous neutralizing antibodies increase with early antiretroviral therapy and shape HIV rebound after treatment interruption. Sci Transl Med. 2023 May 10; 15(695):eabq4490. PMID: 37163616.
Read at: PubMed - Published on 4/10/2023
Adeoye B, Nakiyingi L, Moreau Y, Nankya E, Olson AJ, Zhang M, Jacobson KR, Gupta A, Manabe YC, Hosseinipour MC, Kumwenda J, Sagar M. Mycobacterium tuberculosis disease associates with higher HIV-1-specific antibody responses. iScience. 2023 May 19; 26(5):106631. PMID: 37168567.
Read at: PubMed - Published on 2/1/2023
Basukala B, Rossi S, Bendiks S, Gnatienko N, Patts G, Krupitsky E, Lioznov D, So-Armah K, Sagar M, Cheng C, Henderson AJ. Virally Suppressed People Living with HIV Who Use Opioids Have Diminished Latency Reversal. Viruses. 2023 Feb 01; 15(2). PMID: 36851631.
Read at: PubMed
View 55 more publications: View full profile at BUMC